We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

390 hedge funds and large institutions have $3.64B invested in Takeda Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 308 funds opening new positions, 62 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,322% more first-time investments, than exits

New positions opened: 308 | Existing positions closed: 9

1,500% more funds holding in top 10

Funds holding in top 10: 1 → 16 (+15)

343% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 14

319% more funds holding

Funds holding: 93 → 390 (+297)

300% more capital invested

Capital invested by funds: $910M → $3.64B (+$2.73B)

4.64% more ownership

Funds ownership: 6.8% → 11.43% (+4.6%)

1% less call options, than puts

Call options by funds: $94.4M | Put options by funds: $95.5M

Holders
390
Holders Change
+297
Holders Change %
+319.35%
% of All Funds
8.44%
Holding in Top 10
16
Holding in Top 10 Change
+15
Holding in Top 10 Change %
+1,500%
% of All Funds
0.35%
New
308
Increased
62
Reduced
14
Closed
9
Calls
$94.4M
Puts
$95.5M
Net Calls
-$1.07M
Net Calls Change
-$4.21M

Top Buyers

Rank Fund Capital Flow
1
GCM
Glenview Capital Management
New York
+$525M
2
PC
Paulson & Co
New York
+$267M
3
BG
Baupost Group
Massachusetts
+$215M
4
AC
Adelphi Capital
United Kingdom
+$187M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$152M

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$200M
2
Citigroup
Citigroup
New York
-$127M
3
Bank of America
Bank of America
North Carolina
-$90.5M
4
Goldman Sachs
Goldman Sachs
New York
-$47.1M
5
CS
Credit Suisse
Switzerland
-$23.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
EVM
126
Eaton Vance Management
Massachusetts
$1.17M +$1.15M +57,339 New
US Bancorp
127
US Bancorp
Minnesota
$1.16M +$880K +43,748 +335%
DnB Asset Management
128
DnB Asset Management
Norway
$1.16M +$1.14M +56,719 New
CC
129
CQS Cayman
Cayman Islands
$1.13M – – –
SSA
130
Schonfeld Strategic Advisors
New York
$1.12M +$1.1M +54,900 New
OGC
131
Oak Grove Capital
New Hampshire
$1.1M +$1.09M +53,946 New
CSS
132
Cubist Systematic Strategies
Connecticut
$1.07M +$1.06M +52,484 New
TS
133
Twin Securities
New York
$1.03M +$1.01M +50,369 New
LOAMU
134
Lombard Odier Asset Management (USA)
New York
$1.02M – – –
Brown Advisory
135
Brown Advisory
Maryland
$986K +$975K +48,430 New
Citadel Advisors
136
Citadel Advisors
Florida
$983K -$10.6M -528,806 -92%
TFGT
137
TS Financial Group (TSFG)
Illinois
$974K +$962K +47,795 New
WAM
138
World Asset Management
Michigan
$954K +$461K +22,922 +96%
PI
139
Putnam Investments
Massachusetts
$923K +$912K +45,330 New
AIG
140
American International Group
New York
$910K +$899K +44,656 New
Northwestern Mutual Wealth Management
141
Northwestern Mutual Wealth Management
Wisconsin
$907K +$896K +44,510 New
IAM
142
Integre Asset Management
New York
$859K +$848K +42,159 New
BAM
143
Blueshift Asset Management
New Jersey
$794K +$785K +38,991 New
NEAM
144
New England Asset Management
Connecticut
$793K +$783K +38,932 New
DADC
145
D.A. Davidson & Co
Montana
$791K +$782K +38,837 New
SCM
146
Stevens Capital Management
Pennsylvania
$783K +$774K +38,439 New
KWA
147
KCS Wealth Advisory
California
$782K +$773K +38,394 New
LTFS
148
Ladenburg Thalmann Financial Services
Florida
$779K +$306K +15,203 +66%
Creative Planning
149
Creative Planning
Kansas
$771K +$761K +37,830 New
SC
150
Searle & Co
Connecticut
$758K +$748K +37,196 New
4 5
6
7 8

TAK Hedge Fund Activity: Q1 2019 in Review

390 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2019, worth a combined $3.64B — up 300% from $910M a quarter earlier.

Buyers outnumbered sellers: 308 funds opened new TAK positions and 9 closed out — a net gain of 299 holders — while 62 added to existing stakes and 14 trimmed.

The largest buyer was Glenview Capital Management, opening a new position worth an estimated $525M. The largest seller was UBS Group, cutting an estimated $200M.

  • 390 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2019, up from 93 in Q4 2018.
  • Funds reported $3.64B of Takeda Pharmaceutical stock for Q1 2019, up 300% quarter-over-quarter.
  • 308 funds opened new Takeda Pharmaceutical positions in Q1 2019 and 9 closed out, a net change of +299 holders.
  • The largest Takeda Pharmaceutical buyer in Q1 2019 was Glenview Capital Management, an estimated $525M added.
  • The largest Takeda Pharmaceutical seller in Q1 2019 was UBS Group, an estimated $200M sold.

Based on aggregated 13F filings for Q1 2019.